SCHEMBL14707491

SCHEMBL14707491

CC(=O)Nc1ccc(NS(=O)(=O)c2ccc(Cl)c(-c3nccc4ccccc34)c2)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 1/20 0.52
▸ HTR2A P28223 1/20 0.52
▸ HTR7 P34969 1/20 0.52
▸ HTR6 P50406 1/20 0.52
▸ CKS1B P61024 3/20 0.47
▸ SKP2 Q13309 3/20 0.47
▸ CRHBP P24387 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ SCN9A Q15858 1/20 0.45
▸ KMT2A Q03164 1/20 0.43
▸ ESRRA P11474 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ GRM4 Q14833 1/20 0.42
▸ BDKRB1 P46663 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14707499 0.90 HTR1A (0.50) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13552981 0.89 HTR1A (0.54) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13552931 0.87 HTR1A (0.53) HTR1AHTR2AHTR7HTR6CKS1B
SCHEMBL13552989 0.86 HTR1A (0.52) HTR1AHTR2AHTR7HTR6CRHBP
SCHEMBL13552713 0.86 HTR1A (0.51) HTR1AHTR2AHTR7HTR6CKS1B
SCHEMBL13552747 0.84 POLB (0.50) KMT2AESRRAGRM4ALDH1A1
SCHEMBL14707493 0.84 HTR1A (0.59) HTR1AHTR2AHTR7HTR6TDP1
SCHEMBL13552977 0.84 HTR1A (0.52) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13552978 0.84 HTR1A (0.52) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13044292 0.83 GRM4 (0.46) HTR1AHTR2AHTR7HTR6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9345699-B2 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling NANTBIOSCIENCE, INC. (US) 2016-05-24 — — US disclosed
US-9345699-B2 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling NANTBIOSCIENCE, INC. (US) 2016-05-24 — — US disclosed
US-20140072630-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2014-03-13 — — US disclosed
US-20140072630-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2014-03-13 — — US disclosed
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2013-02-21 — — US disclosed
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2013-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS SHH, GLI1, SMO HTR1A 4175/4885HTR2A 4017/4885HTR7 4272/4885
US-20140072630-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS SHH, GLI1, SMO HTR1A 4175/4885HTR2A 4017/4885HTR7 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback